Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPBWR1 | P48145 | 2/20 | 0.39 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.38 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.38 |
| ▸ | PDE5A | O76074 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | CCR2 | P41597 | 3/20 | 0.36 |
| ▸ | PPARG | P37231 | 1/20 | 0.36 |
| ▸ | KLKB1 | P03952 | 3/20 | 0.35 |
| ▸ | KLK1 | P06870 | 2/20 | 0.35 |
| ▸ | PRKAG1 | P54619 | 2/20 | 0.35 |
| ▸ | PRKAA1 | Q13131 | 2/20 | 0.35 |
| ▸ | PRKAB1 | Q9Y478 | 2/20 | 0.35 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.35 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.35 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21458280 | 1.00 | NPBWR1 (0.39) | NPBWR1EGLN1P2RX3PDE5ATDP1 | |
| SCHEMBL30843280 | 0.91 | NPBWR1 (0.39) | NPBWR1EGLN1P2RX3TDP1KLKB1 | |
| SCHEMBL21458219 | 0.91 | NPBWR1 (0.39) | NPBWR1EGLN1P2RX3TDP1KLKB1 | |
| SCHEMBL24992167 | 0.82 | CRHR1 (0.39) | PDE5A | |
| SCHEMBL30843267 | 0.82 | PTGER4 (0.40) | P2RX3KLKB1KLK1PTGER4 | |
| SCHEMBL21458242 | 0.82 | PTGER4 (0.40) | P2RX3KLKB1KLK1PTGER4 | |
| SCHEMBL21481962 | 0.80 | CHRM4 (0.35) | KLKB1KLK1PTGER4 | |
| SCHEMBL21458140 | 0.80 | CHRM4 (0.35) | KLKB1KLK1PTGER4 | |
| SCHEMBL21481961 | 0.77 | CNR2 (0.40) | PDE5AMTNR1AMTNR1B | |
| SCHEMBL21481971 | 0.77 | CRHR1 (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250353829-A1 | BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF | TEMPEST THERAPEUTICS INC (US) | 2025-11-20 | — | — | US | disclosed |
| CN-112313208-B | Bicyclic carboxamides and methods of use thereof | 泰普斯特医疗公司 | 2024-04-19 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250353829-A1 | BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF | PTGER4, PTGER2, CNR2 | NPBWR1 635/4885EGLN1 336/4885P2RX3 70/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.